ADVERTORIAL – Sponsored by Alexion, AstraZeneca Rare Disease

^PrUltomiris^® (ravulizumab) now publicly reimbursed for adult anti-AchR-antibody-positive generalized myasthenia gravis in Ontario, Alberta, Nova Scotia, Saskatchewan, Newfoundland and Labrador, and NIHB

Alexion, AstraZeneca Rare Disease is pleased to announce that as of March 26, 2026, ravulizumab (Ultomiris) is listed in Ontario through the Exceptional Access Program (EAP) for the treatment of adult patients with anti-anticholinergic receptor (AChR) antibody-positive generalized myasthenia gravis (gMG). Read More

ADVERTORIAL – Sponsored by Alexion, AstraZeneca Rare Disease

^PrUltomiris^® (ravulizumab) now publicly reimbursed for adult anti-AQP4 antibody-positive NMOSD in Ontario, Quebec, Alberta, Nova Scotia, Saskatchewan, and NIHB

Alexion, AstraZeneca Rare Disease is pleased to announce that as of January 20^th, 2026, ravulizumab (Ultomiris) is now listed on the Ontario Drug Benefit program for the treatment of adult patients with anti-aquaporin 4 (AQP4) antibody-positive neuromyelitis optica spectrum disease (NMOSD). Read More